We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $519M
1-Year Est. Return 339.42%
This Fund
S&P 500
This Quarter Est. Return
+35.22%
1 Year Est. Return
+339.42%
3 Year Est. Return
+563.8%
5 Year Est. Return
+1,003.88%
10 Year Est. Return
–
AUM
$276M
AUM Growth
+$95.9M
Cap. Flow
+$36.2M
Cap. Flow %
13.11%
Top 10 Hldgs %
100%
Holding
7
New
1
Increased
2
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$78.9M
2
PHVS icon
Pharvaris
PHVS
+$19.2M
3
ELEV
Elevation Oncology
ELEV
+$2.76M

Top Sells

Rank Stock Value
1
VTYX
Ventyx Biosciences
VTYX
+$64.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLRN
1
DELISTED
ACELYRIN
SLRN
$80.6M 29.18%
+3,857,230
New +$78.9M
ALXO icon
2
ALX Oncology
ALXO
$277M
$72.8M 26.36%
9,699,925
– –
PHVS icon
3
Pharvaris
PHVS
$2.48B
$64.6M 23.37%
4,264,672
+1,986,097
+87% +$19.2M
HRMY icon
4
Harmony Biosciences
HRMY
$2.28B
$36.4M 13.19%
1,035,396
– –
VTYX
5
DELISTED
Ventyx Biosciences
VTYX
$13.9M 5.03%
424,032
-1,874,801
-82% -$64.6M
ELEV
6
DELISTED
Elevation Oncology
ELEV
$4.43M 1.6%
2,914,255
+1,047,916
+56% +$2.76M
IMPL
7
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$3.5M 1.27%
2,759,791
– –

Similar funds

CFA
Churchill Financial Advisors Louisville, Kentucky $519M AUM
CFG
Compton Financial Group Towson, Maryland $519M AUM 14.76% 1-Year Est. Return
MWM
Mindset Wealth Management Indianapolis, Indiana $519M AUM 46.03% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $520M AUM 21.73% 1-Year Est. Return
WS
Wendel SE Paris $519M AUM 48.2% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
MWC
MBM Wealth Consultants Chesterfield, Missouri $519M AUM 16.88% 1-Year Est. Return
PDIP
Palo Duro Investment Partners Chicago, Illinois $518M AUM 22.62% 1-Year Est. Return

venBio Partners's Q2 2023 Portfolio in Review

As of Q2 2023, venBio Partners held 7 positions worth $276M, up 53% from $180M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners deployed $36.2M of net new capital in Q2 2023, opening 1 new position and adding to 2 existing holdings. Its largest new stake was ACELYRIN: 3,857,230 shares worth $80.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Ventyx Biosciences, an estimated $64.6M trimmed.

  • venBio Partners's largest Q2 2023 buy was ACELYRIN: 3,857,230 shares worth $80.6M.
  • venBio Partners added most to Pharvaris in Q2 2023, an estimated $19.2M increase.
  • venBio Partners's biggest Q2 2023 reduction was Ventyx Biosciences, cutting an estimated $64.6M.
  • venBio Partners's ten largest holdings make up 100% of its $276M portfolio in Q2 2023.
  • venBio Partners opened 1 new position and closed 0 in Q2 2023.
  • venBio Partners's portfolio value rose 53% quarter-over-quarter to $276M.

Based on venBio Partners's 13F filing for Q2 2023, filed 14 Aug 2023.